Vanda Pharmaceuticals Inc. (VNDA)
NASDAQ: VNDA · Real-Time Price · USD
6.72
-0.03 (-0.44%)
Dec 11, 2025, 2:12 PM EST - Market open
Vanda Pharmaceuticals Revenue
Vanda Pharmaceuticals had revenue of $56.26M in the quarter ending September 30, 2025, with 18.06% growth. This brings the company's revenue in the last twelve months to $212.07M, up 11.12% year-over-year. In the year 2024, Vanda Pharmaceuticals had annual revenue of $198.77M with 3.18% growth.
Revenue (ttm)
$212.07M
Revenue Growth
+11.12%
P/S Ratio
1.87
Revenue / Employee
$576,288
Employees
368
Market Cap
397.13M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 198.77M | 6.13M | 3.18% |
| Dec 31, 2023 | 192.64M | -61.74M | -24.27% |
| Dec 31, 2022 | 254.38M | -14.30M | -5.32% |
| Dec 31, 2021 | 268.68M | 20.51M | 8.27% |
| Dec 31, 2020 | 248.17M | 20.98M | 9.23% |
| Dec 31, 2019 | 227.19M | 34.07M | 17.64% |
| Dec 31, 2018 | 193.12M | 28.04M | 16.98% |
| Dec 31, 2017 | 165.08M | 19.07M | 13.06% |
| Dec 31, 2016 | 146.02M | 36.09M | 32.83% |
| Dec 31, 2015 | 109.93M | 59.77M | 119.16% |
| Dec 31, 2014 | 50.16M | 16.28M | 48.05% |
| Dec 31, 2013 | 33.88M | 1.15M | 3.52% |
| Dec 31, 2012 | 32.73M | 1.46M | 4.66% |
| Dec 31, 2011 | 31.27M | -4.44M | -12.43% |
| Dec 31, 2010 | 35.71M | 31.16M | 685.16% |
| Dec 31, 2009 | 4.55M | - | - |
| Dec 31, 2008 | - | - | - |
| Dec 31, 2007 | - | - | - |
| Dec 31, 2006 | - | - | - |
| Dec 31, 2005 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
VNDA News
- 6 days ago - FDA Lifts Partial Clinical Hold on Tradipitant for Motion Sickness - PRNewsWire
- 11 days ago - Should You Invest in This Under-the-Radar Weight Loss Stock? - The Motley Fool
- 13 days ago - Vanda Pharmaceuticals Provides Regulatory Update on Tradipitant for Motion Sickness - PRNewsWire
- 20 days ago - Vanda Pharmaceuticals: Commercial Execution Meets Pipeline Optionality - Seeking Alpha
- 23 days ago - Side Effects From Wegovy? This Vanda Pharmaceuticals' Drug Halves Vomiting In Patients - Benzinga
- 23 days ago - Vanda Pharmaceuticals Reports Positive Results for Tradipitant in Preventing GLP-1 Induced Nausea and Vomiting - PRNewsWire
- 5 weeks ago - Vanda Pharmaceuticals Announces Participation in the Stifel 2025 Healthcare Conference - PRNewsWire
- 6 weeks ago - Vanda Pharmaceuticals Inc. (VNDA) Q3 2025 Earnings Call Transcript - Seeking Alpha